SCHEMBL4655730

SCHEMBL4655730

COC(=O)CCOc1cc(C)ccc1Cl

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.59
CYP2C19 P33261 3/20 0.59
HPGD P15428 3/20 0.59
L3MBTL1 Q9Y468 3/20 0.59
ALDH1A1 P00352 2/20 0.59
MAPK1 P28482 2/20 0.59
CYP2C9 P11712 2/20 0.59
MEN1 O00255 1/20 0.59
USP2 O75604 1/20 0.59
POLB P06746 1/20 0.59
ALOX12 P18054 1/20 0.59
KMT2A Q03164 1/20 0.59
NPSR1 Q6W5P4 1/20 0.59
LMNA P02545 2/20 0.50
CYP1A2 P05177 2/20 0.50
CYP3A4 P08684 2/20 0.50
KDM4E B2RXH2 3/20 0.49
ATM Q13315 2/20 0.49
HSD17B10 Q99714 1/20 0.48
NPC1 O15118 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10359263 0.91 MAPT (0.65) MAPTCYP2C19HPGDL3MBTL1ALDH1A1
SCHEMBL13959568 0.84 LMNA (0.71) MAPTCYP2C19HPGDL3MBTL1ALDH1A1
SCHEMBL21991843 0.84 TSHR (0.67) HPGDL3MBTL1ALDH1A1CYP2C9MEN1
SCHEMBL7827993 0.81 TSHR (0.71) MAPTCYP2C19HPGDL3MBTL1ALDH1A1
SCHEMBL12900938 0.80 MAPT (0.56) MAPTCYP2C19HPGDL3MBTL1ALDH1A1
SCHEMBL11196941 0.80 KMT2A (0.59) MAPTCYP2C19HPGDL3MBTL1ALDH1A1
SCHEMBL13861973 0.77 L3MBTL1 (0.75) MAPTCYP2C19HPGDL3MBTL1ALDH1A1
SCHEMBL18122081 0.77 MAPT (0.65) MAPTCYP2C19HPGDL3MBTL1ALDH1A1
SCHEMBL10358917 0.77 MAPT (0.65) MAPTCYP2C19HPGDL3MBTL1ALDH1A1
SCHEMBL19607315 0.76 L3MBTL1 (0.64) MAPTCYP2C19HPGDL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101410396-A Chromane derivatives RAQUALIA PHARMA INC (JP) 2009-04-15 CN disclosed
EP-1996589-A1 CHROMANE DERIVATIVES RaQualia Pharma Inc (JP) 2008-12-03 EP disclosed
WO-2007107827-A1 CHROMANE DERIVATIVES RAQUALIA PHARMA INC. (JP) 2007-09-27 WO disclosed
US-20070219237-A1 Chromane Derivatives PFIZER INC 2007-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219237-A1 Chromane Derivatives HRH2, HRH1, CHRM1 MAPT 4857/4885CYP2C19 690/4885HPGD 534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.